CD274 and head and neck squamous cell carcinoma: INBRX-106, a hexavalent OX40 agonist designed for enhanced receptor clustering, has generated renewed interest and is currently being investigated in combination with pembrolizumab in a phase II/III trial for the first-line treatment of advanced HNSCC with a PD-L1-combined positive score (CPS) > 20 [92].